Knowledge Gaps and Educational Needs Among Patients Receiving Long-Acting Injectable Cabotegravir/Rilpivirine: A Multisite Cross-Sectional Survey
Olivia Youngblood, Elizabeth Lyden, Yijun Lu, Aniruddha Hazra, Kaylie Miller, Jennifer O’Neill, Maureen Kubat, Shawnalyn W. Sunagawa, Joshua P. Havens, Jennifer M. Davis, Sara H. Bares
Long-acting injectable antiretroviral therapy (LAI ART) offers an alternative to daily ART by mitigating adherence barriers such as pill fatigue and stigma. However, it introduces new challenges, including the need for continued engagement, clear communication, and understanding of the consequences of missed or delayed doses. Patient knowledge of these issues remains poorly characterized. Between June 1 and October 2, 2025, we administered a structured survey to individuals receiving LAI ART at two academic medical centers to assess sociodemographic characteristics, knowledge of key treatment concepts (injection schedules, dosing windows, oral bridging indications, and consequences of delayed or missed doses), and treatment perceptions. Eight questions were used to assess LAI ART-related knowledge among participants. Associations were evaluated using Fisher’s exact tests (